Stifel analyst Jonathan Block upgraded Inspire Medical (INSP) to Buy from Hold with a price target of $110, up from $100. The company’s headwinds are easing following Friday night’s large positive reimbursement revision, the analyst tells investors in a research note. Stifel sees Inspire’s headwinds turning into tailwinds, including patient warehousing, which it believes will now likely aid 2026 volumes. In addition, Inspire’s advertising spend, which was curtailed notably in 2024 and early-2025, has picked up lately, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Positive Outlook for Inspire Medical Systems: Increased Reimbursement Rates and Strategic Advantages Drive Buy Rating
- Inspire Medical sees $90M-$100M income tax benefit for FY25
- Inspire Medical Systems to Release Tax Valuation Allowance
- Inspire Medical Faces Legal Heat Over Product Launch
- Inspire Medical participates in a conferene call with JPMorgan